NewAmsterdam Pharma Company NAMS Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's operating lease liabilities?
- NewAmsterdam Pharma Company (NAMS) reported operating lease liabilities of $66K in Q4 2025.
- How has NewAmsterdam Pharma Company's operating lease liabilities changed year-over-year?
- NewAmsterdam Pharma Company's operating lease liabilities decreased by 67.3% year-over-year, from $202K to $66K.
- What is the long-term trend for NewAmsterdam Pharma Company's operating lease liabilities?
- Over 2 years (2022 to 2025), NewAmsterdam Pharma Company's operating lease liabilities has grown at a 4.9% compound annual growth rate (CAGR), from $60K to $66K.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.